Trial Profile
A 6-week Open-label, Randomised, Multicentre, Phase IIIb, Parallel-group Study to Compare the Efficacy and Safety of Rosuvastatin (10 mg) with Atorvastatin (20 mg) in Subjects with Hypercholesterolaemia and Either a History of Coronary Heart Disease (CHD) or Clinical Evidence of Atherosclerosis or a CHD Risk Equivalent (10-year Risk Score of >20%)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Sep 2008
Price :
$35
*
At a glance
- Drugs Rosuvastatin (Primary) ; Atorvastatin
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms PULSAR
- Sponsors AstraZeneca
- 10 Sep 2008 New trial record.